Healthcare Realty Trust's analyst price target has been revised slightly upward to $18.70 from $18.56 as analysts factor in modest improvements in projected profit margin and discount rate, even though the outlook for revenue growth is marginally lower.
What's in the News
- The company reported impairments of real estate assets totaling $140,877,000 for the second quarter ended June 30, 2025, up from $120,917,000 a year prior (Key Developments).
- Earnings guidance for 2025 was lowered. Projected loss per share is now expected to be in the range of $0.78 to $0.73, compared to prior guidance of $0.28 to $0.20 (Key Developments).
- The Board approved a common stock dividend of $0.24 per share to be paid on August 28, 2025, to Class A common stockholders of record as of August 14, 2025. Eligible operating partnership unit holders will receive an equivalent distribution (Key Developments).
- As of June 30, 2025, the company completed the buyback of 3,679,162 shares, representing 1.03 percent for $63.04 million under its current buyback program. No shares were repurchased in the most recent tranche (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has risen slightly, now at $18.70 per share compared to $18.56 previously.
- Discount Rate decreased slightly, moving from 8.27% to 8.23%.
- Revenue Growth projections have fallen, with the estimate shifting from -1.15% to -1.38%.
- Net Profit Margin has improved modestly, increasing from 23.08% to 23.31%.
- Future P/E ratio is marginally higher at 29.76x, up from 29.64x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.